Last updated: February 21, 2026
What is the drug associated with NDC 72888-0149?
The NDC 72888-0149 corresponds to Ceritinib (ZDASICA), an oral ALK inhibitor approved by the FDA for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in adult patients who have progressed on or are intolerant to crizotinib.[1]
What is the current market landscape?
Market Size and Growth
- The global NSCLC treatment market was valued at approximately USD 8 billion in 2022.
- Compound annual growth rate (CAGR) estimated at 8% from 2022-2027.[2]
- The ALK inhibitor segment accounts for roughly 12% of the NSCLC market, translating to USD 960 million in 2022.
Competitive Positioning
- Mycobacterium terapies such as Alecensa (alectinib) and Xalkori (crizotinib) dominate the ALK inhibitor space.
- Ceritinib’s sales in 2022 approximated USD 350 million, reflecting its importance but also its market share relative to competitors.
- The 2023 FDA label updates permit use in systemic therapy following resistance to other ALK inhibitors, expanding its potential patient base.
Patent Status and Market Exclusivity
- Original patent expired in 2021; however, recent patent applications provide data exclusivity until 2030.
- The entry of generics is expected post-2030, which could drastically reduce prices.
What are the key factors influencing pricing and market penetration?
Clinical Efficacy and Safety
- Ceritinib shows a median progression-free survival (PFS) of approximately 16 months.
- Approval expands patient eligibility, impacting overall demand.
Reimbursement Landscape
- Historically, payers have reimbursed for branded ceritinib at USD 9,000–USD 12,000 per month.
- Price negotiations and formulary decisions vary by country and insurer.
Cost of Goods and Manufacturing
- Approximate manufacturing cost per unit estimated at USD 1,200.
- Economies of scale could reduce manufacturing costs by 15–20% with increased volume.
Market Dynamics
- The introduction of next-generation ALK inhibitors, such as lorlatinib, affects market share.
- Physician preference and prescribing patterns lean towards agents with better CNS penetration or fewer side effects.
What are the price projections through 2030?
Short-Term (2023–2025)
- Existing prices will remain stable pending patent expiry.
- Modest discounts (5–10%) expected in negotiations as generic options approach.
| Year |
Estimated Average Monthly Price |
Market Impact Estimate |
| 2023 |
USD 10,500 |
Stable; incumbency of branded drug |
| 2024 |
USD 10,200 – USD 10,500 |
Slight erosion; negotiation leverage |
| 2025 |
USD 10,000 – USD 10,300 |
Increased competition pressures |
Mid to Long Term (2026–2030)
- Price declines anticipated with introduction of generics or biosimilars post-2030.
- Forecasted decline of 30–50% over five years post-generic entry, aligning with similar oncology drugs.
| Year |
Projected Average Monthly Price |
Comments |
| 2026 |
USD 7,500 – USD 8,500 |
Early generic entry possible |
| 2028 |
USD 5,000 – USD 6,500 |
Generic market penetration increases |
| 2030 |
USD 3,500 – USD 4,500 |
Maximum price reduction, volume driven |
What are the key uncertainties?
- The timing of patent expiration and regulatory pathways for biosimilar entry.
- Market adoption rates driven by clinical guidelines and physician preferences.
- Reimbursement policies differing across global markets.
- The pace of clinical development of next-generation ALK inhibitors.
Conclusion
- Ceritinib remains a mid to high-price oncology therapy through 2025.
- Its market share will depend on physician adoption, reimbursement policies, and competition.
- Post-2030, prices are expected to decline significantly, with generics capturing a majority of the market.
Key Takeaways
- Current annual US market sales approximate USD 350 million.
- Regulatory and patent factors shape future pricing.
- Price erosion is forecasted post-2030, driven by generic availability.
- Competition from newer ALK inhibitors influences both demand and pricing.
- Manufacturers should monitor patent expiry, biosimilar development, and clinical guidelines for strategic positioning.
FAQs
1. When will generics likely impact ceritinib’s price?
Post-2030, following patent expiration and regulatory approval of biosimilars or generics.[3]
2. How do clinical advances influence pricing?
Newer agents with improved efficacy or safety profiles may reduce demand, decreasing prices for existing drugs.
3. What pricing strategies could pharma companies use?
Volume-based discounts, patient assistance programs, and tiered pricing to manage market share and revenue.
4. How does reimbursement vary globally?
US payers reimburse at higher rates; European markets often negotiate lower prices under national health systems.
5. What are the primary barriers to market growth?
Competitive drugs, physician preference, healthcare reforms, and patent landscapes.
References
- U.S. Food and Drug Administration. (2014). Zykadia (ceritinib) prescribing information.
- GlobalData. (2022). NSCLC market analysis report.
- IQVIA. (2022). Global oncology drug pricing and reimbursement report.
